Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Houston, Texas and Tübingen, Germany, September 6, 2024 – Immatics NV (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine IMA203 targeting PRAME, will be presented on the 21st^st International Congress of the Society for Melanoma Research.

Oral presentation